Skip to Content
Merck
All Photos(1)

Documents

15236

Sigma-Aldrich

N,O-Bis(trimethylsilyl)carbamate

≥98.0% (T)

Synonym(s):

BSC, Trimethylsilyl N-(trimethylsilyl)carbamate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
(CH3)3SiNHCO2Si(CH3)3
CAS Number:
35342-88-2
Molecular Weight:
205.40
Beilstein:
2043399
EC Number:
252-520-4
MDL number:
MFCD00040476
UNSPSC Code:
12352100
PubChem Substance ID:
329750791
NACRES:
NA.22

Quality Level

100

Assay

≥98.0% (T)

form

solid

mp

77-83 °C

SMILES string

C[Si](C)(C)NC(=O)O[Si](C)(C)C

InChI

1S/C7H19NO2Si2/c1-11(2,3)8-7(9)10-12(4,5)6/h1-6H3,(H,8,9)

InChI key

DGIJAZGPLFOQJE-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Other Notes

Extremely suitable reagent for the silylation of alcohols, phenols and carboxylic acids. The only by-products are CO2 and NH3; Silyloxycarbonylation of amines; Acylisocyanates from carboxylic acid chlorides

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
048627/1V
048627/1
048627/1V
048627/1
48627/1

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Abi Vijenthira et al.
Blood, 136(25), 2881-2892 (2020-10-29)
Outcomes for patients with hematologic malignancy infected with COVID-19 have not been aggregated. The objective of this study was to perform a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. We
V.P. Kozyukov et al.
Current Chemical Reactions, 2, 6251-6251 (1980)
V.P. Kozyukov et al.
Zhur. Obshch. Khim., 51, 239-239 (1981)
Barbara Melosky et al.
The oncologist, 25(1), 64-77 (2019-05-30)
Lung cancer is one of the most common types of cancer, resulting in approximately 1.8 million deaths worldwide. Immunotherapy using checkpoint inhibitors has become standard of care in advanced non-small cell lung cancer (NSCLC), and there is increasing interest in
Filippo Pelizzaro et al.
Cancers, 13(4) (2021-03-07)
We aimed at assessing the impact of surveillance on long-term survival in HCC patients. From the ITA.LI.CA database, we selected 1028 cases with long (≥5 years, LS group) and 2721 controls with short-term survival (<5 years, SS group). The association
View All Related Papers

Articles

Silylation of Non-Steroidal Anti-Inflammatory Drugs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Silylation of Non-Steroidal Anti-Inflammatory Drugs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Silylation of Non-Steroidal Anti-Inflammatory Drugs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Silylation of Non-Steroidal Anti-Inflammatory Drugs

Results of a study involving the ability few Fluka silylating reagents to form GC-MS-compatible trimethylsilylmethyl derivatives of NSAIDs

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service